CNS Pharmaceuticals, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
CNS Pharmaceuticals, Inc. (CNSP) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 26.35 million shares for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-03-03
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 27.84M shares, a 62.90% increase year-over-year.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 27.44M shares, a 66.49% increase year-over-year.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 25.43M shares, a 54.60% increase year-over-year.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 24.66M shares, a 49.93% increase year-over-year.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 26.35M shares, a 58.58% increase from fiscal 2020.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 16.62M shares, a 21.77% increase from fiscal 2019.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 13.65M shares, a 29.85% increase from fiscal 2018.
- CNS Pharmaceuticals, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 10.51M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | 27.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 27.64M shares derived: average of 2 quarters · filed 2022-03-03 | 26.90M shares derived: average of 3 quarters · filed 2022-03-03 | 26.35M shares 10-K · filed 2022-03-03 |
| 2021-09-30 | 27.44M shares 10-Q · filed 2021-11-12 | 26.44M shares derived: average of 2 quarters · filed 2021-11-12 | 25.86M shares 10-Q · filed 2021-11-12 | 23.66M shares derived: average of 4 quarters · filed 2022-03-03 |
| 2021-06-30 | 25.43M shares 10-Q · filed 2021-08-13 | 25.06M shares 10-Q · filed 2021-08-13 | 22.40M shares derived: average of 3 quarters · filed 2022-03-03 | 20.92M shares derived: average of 4 quarters · filed 2022-03-03 |
| 2021-03-31 | 24.66M shares 10-Q · filed 2021-05-13 | 20.88M shares derived: average of 2 quarters · filed 2022-03-03 | 19.41M shares derived: average of 3 quarters · filed 2022-03-03 | 18.67M shares derived: average of 4 quarters · filed 2022-03-03 |
| 2020-12-31 | 17.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | 16.79M shares derived: average of 2 quarters · filed 2022-03-03 | 16.67M shares derived: average of 3 quarters · filed 2022-03-03 | 16.62M shares 10-K · filed 2022-03-03 |
| 2020-09-30 | 16.48M shares 10-Q · filed 2021-11-12 | 16.47M shares derived: average of 2 quarters · filed 2021-11-12 | 16.46M shares 10-Q · filed 2021-11-12 | 16.11M shares derived: average of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | 16.45M shares 10-Q · filed 2021-08-13 | 16.45M shares 10-Q · filed 2021-08-13 | 15.99M shares derived: average of 3 quarters · filed 2021-08-13 | 15.39M shares derived: average of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | 16.45M shares 10-Q · filed 2021-05-13 | 15.76M shares derived: average of 2 quarters · filed 2021-05-13 | 15.03M shares derived: average of 3 quarters · filed 2021-05-13 | 14.57M shares derived: average of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | 15.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | 14.32M shares derived: average of 2 quarters · filed 2021-02-12 | 13.95M shares derived: average of 3 quarters · filed 2021-02-12 | 13.65M shares 10-K · filed 2021-02-12 |
| 2019-09-30 | 13.57M shares 10-Q · filed 2020-11-12 | 13.39M shares derived: average of 2 quarters · filed 2020-11-12 | 13.17M shares 10-Q · filed 2020-11-12 | 12.51M shares derived: average of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | 13.20M shares 10-Q · filed 2020-08-10 | 12.96M shares 10-Q · filed 2020-08-10 | 12.15M shares derived: average of 3 quarters · filed 2020-08-10 | 11.74M shares derived: average of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | 12.69M shares 10-Q · filed 2020-05-15 | 11.63M shares derived: average of 2 quarters · filed 2020-05-15 | 11.25M shares derived: average of 3 quarters · filed 2020-05-15 | |
| 2018-12-31 | 10.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | 10.53M shares derived: average of 2 quarters · filed 2020-03-12 | 10.51M shares 10-K · filed 2020-03-12 | |
| 2018-09-30 | 10.49M shares 10-Q · filed 2019-12-20 | 10.49M shares 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |